Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial

BACKGROUND: The phase II AFUGEM GERCOR trial aimed to assess the efficacy of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine (gemcitabine group) or simplified leucovorin and fluorouracil (sLV5FU2 group) in patients with previously untreated metastatic pancreatic cancer. Results...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Med
Main Authors: Charton, Emilie, Bachet, Jean‐Baptiste, Hammel, Pascal, Desramé, Jérôme, Chibaudel, Benoist, Cohen, Romain, Debourdeau, Philippe, Dauba, Jérome, Lecomte, Thierry, Seitz, Jean‐François, Tournigand, Christophe, Aparicio, Thomas, Guerin‐Meyer, Véronique, Taieb, Julien, Volet, Julien, Louvet, Christophe, Anota, Amélie, Bonnetain, Franck
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2019
Subjects:
Clinical Cancer Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718524/
https://ncbi.nlm.nih.gov/pubmed/31314957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2311
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items